Investor
Defilade Capital Management, L.P.
CIK 0002088557 · filed 2026-05-14 · SEC filing
13F book
$712.2M
Positions
31
9 new · 11 sold
Largest name
7.4%
Zimmer Biomet Holdings, Inc. · ZBH
Est. mark
−$28.2M
Price effect on 22 names still held. Flow $2.67M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 579.2K | $52.4M | 7.4% | — | New |
| Henry Schein Inc | HSIC | 624K | $46M | 6.5% | −$602.4K | Added$21.8M |
| Becton Dickinson & Co | BDX | 279.2K | $43.9M | 6.2% | −$2.99M | Added$28.1M |
| Ptc Therapeutics, Inc. | PTCT | 376.2K | $41.1M | 5.8% | — | New |
| Dexcom Inc | DXCM | 538.8K | $33.8M | 4.8% | −$874.2K | Added$17.6M |
| Icu Med Inc | — | 254.3K | $32.8M | 4.6% | −$3.44M | Cut−$15.8M |
| Insmed Inc | INSM | 194.9K | $31.9M | 4.5% | −$526K | Added$23.2M |
| Intuitive Surgical Inc | ISRG | 67.7K | $31.2M | 4.4% | −$4.81M | Added$5.34M |
| Revolution Medicines Inc | — | 316K | $30.7M | 4.3% | $5.56M | Cut$1.78M |
| Globus Med Inc | — | 354.4K | $30.5M | 4.3% | −$307.3K | Added$7.2M |
| Neurocrine Biosciences Inc | NBIX | 209.9K | $27.7M | 3.9% | — | New |
| Denali Therapeutics Inc. | DNLI | 1.36M | $26.1M | 3.7% | $1.77M | Added$15.3M |
| PACS Group, Inc. | PACS | 604.2K | $25.6M | 3.6% | $2.43M | Cut−$18.3M |
| Olema Pharmaceuticals, Inc. | OLMA | 1.5M | $22.4M | 3.1% | −$12.5M | Added−$8.43M |
| Elanco Animal Health Inc | ELAN | 931.1K | $22.3M | 3.1% | $521.7K | Added$13.2M |
| Pfizer Inc | PFE | 1.46M | $19.4M | 2.7% | −$17.1M | Cut−$35.5M |
| Eli Lilly & Co | LLY | 20.7K | $19M | 2.7% | −$3.21M | Cut−$15.3M |
| Lantheus Hldgs Inc | — | 249.4K | $18.9M | 2.7% | — | New |
| Integer Hldgs Corp | — | 213K | $18.7M | 2.6% | — | New |
| Biogen Inc. | BIIB | 96.3K | $17.7M | 2.5% | $706.8K | Cut−$10.9M |
| Evommune, Inc. | EVMN | 678.6K | $15.6M | 2.2% | $1.26M | Added$11.9M |
| Tandem Diabetes Care Inc | TNDM | 761.9K | $14.6M | 2.1% | — | New |
| Cogent Biosciences, Inc. | COGT | 352.6K | $13.6M | 1.9% | $1.05M | Cut−$6.63M |
| Nuvalent Inc | — | 129.9K | $13.3M | 1.9% | $241.7K | Cut−$13.7M |
| Ocular Therapeutix, Inc | OCUL | 1.49M | $12.6M | 1.8% | −$2.5M | Added$4.32M |
| Ascendis Pharma A/S | ASND | 51.9K | $11.9M | 1.7% | $803.9K | Cut−$6.4M |
| Align Technology Inc | ALGN | 67.3K | $11.5M | 1.6% | $1.03M | Cut−$8.45M |
| Eledon Pharmaceuticals, Inc. | ELDN | 3.56M | $11M | 1.5% | $5.17M | Added$6.01M |
| Oric Pharmaceuticals, Inc. | ORIC | 842.9K | $10.7M | 1.5% | — | New |
| Biohaven Ltd. | BHVN | 315.9K | $2.67M | 0.4% | — | New |
| Mereo Biopharma Group Plc | MREO | 7.56M | $2.49M | 0.4% | — | New |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.